摘要
目的探讨血清正五聚蛋白3(PTX3)、心型脂肪酸结合蛋白(H-FABP)与风湿性心脏病(风心病)患者心功能的相关性。方法选择2016年9月至2018年9月于文昌市人民医院接诊的55例风心病患者为观察组,并选择我院同期体检健康者50例为对照组,分析血清PTX3、H-FABP与左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)的相关性。结果观察组患者的PTX3、H-FABP、LVEDD水平显著高于对照组,LVEF水平显著低于对照组(P<0.05);Ⅱ级心功能患者的PTX3、H-FABP、LVEDD水平显著低于Ⅲ级、Ⅳ级心功能患者,Ⅱ级心功能患者LVEF水平显著高于Ⅲ级、Ⅳ级心功能患者(P<0.05);将LVEF、LVEDD作为因变量,将血清PTX3、H-FABP分别作为自变量,在相关性分析结果中显示,PTX3、H-FABP和LVEF间均呈负相关(r=-0.610,-0.850,P<0.05),PTX3、H-FABP和LVEDD间均呈正相关(r=0.461,0.641,P<0.05)。结论在风心病患者中PTX3、H-FABP的表达和病情严重程度间存在密切关系,可促使疾病进展。
Objective To discuss the correlation among pentraxins 3(PTX3),heart fatty acid binding protein(H-FABP)and heart function in patients with rheumatic heart disease(RHD).Methods RHD patients were chosen into observation group(n=55)and meanwhile healthy controls were chosen into control group(n=50)from People’s Hospital of Wenchang City from Sept.2016 to Sept.2018.The correlation among PTX3,H-FABP,left ventricular ejection fraction(LVEF)and left ventricular end-diastolic inner diameter(LVEDd)were analyzed.Results The levels of PTX3,H-FABP and LVEDd were significantly higher,and LVEF level was significantly lower in observation group than those in control group(P<0.05).The levels of PTX3,H-FABP and LVEDd were significantly lower,and LVEF level was significantly higher in patients with heart function grade II than those in patients with heart function grades III and IV(P<0.05).Taken LVEF and LVEDD as dependent variables and PTX3 and H-FABP as independent variables,the results of correlation analysis showed that PTX3 and H-FABP were negatively correlated to LVEF(r=-0.610,-0.850,P<0.05),and PTX3 and H-FABP were positively correlated to LVEDd(r=0.461,0.641,P<0.05).Conclusion The expressions of PTX3 and H-FABP are closely related to severity of disease condition,which can improve disease development in RHD patients.
作者
黄循正
邱林美
韩叶光
李春芳
Huang Xunzheng;Qiu Linmei;Han Yeguang;Li Chunfang(Department of Cardiology,People's Hospital of Wenchang City,Hainan Province,Wenchang 571300,China)
出处
《中国循证心血管医学杂志》
2019年第9期1112-1114,共3页
Chinese Journal of Evidence-Based Cardiovascular Medicine
